Senolytic Stack (Fisetin + Quercetin).

Fisetin is one of the two flavonols the combination is built from, so a formula carrying both is stacking the same molecule. The relevant check is total flavonol load rather than a new mechanism.

Quercetin is the second flavonol in the pair and shares fisetin's flavonol backbone, conjugation route and metal-binding behaviour. Adding standalone quercetin raises exposure to the same chemistry.

Piperine slows UGT glucuronidation and sulfotransferase activity in the gut wall and liver, the routes that clear flavonols fastest. Less first-pass conjugation means more of the parent flavonol circulates.

Both flavonols are poorly water soluble, and phospholipid complexing disperses them into mixed micelles the small intestine can take up. This is the long-standing phytosome approach to flavonoid delivery.

Ascorbate reduces the flavonoid phenoxyl radical back to the parent flavonol after it has quenched an oxidant. The pair recycles rather than each acting alone.

Quercetin acts as a zinc ionophore, carrying zinc ions across lipid membranes that they otherwise cross slowly. The flavonol changes where zinc ends up rather than how much is absorbed.

Quercetin and related flavones inhibit CD38, the main ectoenzyme that consumes NAD and its precursors. Slowing that consumption leaves more of a supplied precursor available to the salvage pathway.

CD38 degrades NAD precursors, and flavonol inhibition of that enzyme reduces the loss. The flavonol acts on the sink while the riboside supplies the source.

Apigenin inhibits CD38 through the same flavone binding site the flavonols use, so the two act on one target rather than two. Combining them mainly raises occupancy of that single enzyme.

Sulforaphane modifies KEAP1 cysteines to release Nrf2 and switch on the phase II response, the same transcriptional arm that flavonols touch more weakly. Their entry points into that pathway differ.

EGCG and the flavonols compete for the same UGT and sulfotransferase capacity and for efflux transporters in the gut wall. Taken together the exposure of each shifts, so dose response measured alone does not carry over.

Flavonols carry catechol and hydroxyl groups that bind ferrous and ferric iron in the gut lumen and hold it in a form the enterocyte does not take up. Separating the doses by a couple of hours keeps iron uptake normal.

Quercetin binds copper avidly at the same catechol site it uses for iron, which changes how much free copper is available for uptake. The interaction is well described in solution chemistry.

Luteolin and the two flavonoids in this pairing are conjugated by the same UGT and SULT enzymes in the gut wall and liver. Loading several flavonoids at once occupies that conjugation capacity, which is the proposed reason a blend may show more circulating aglycone than a single flavonoid at the same dose. The overlap is mechanistic and read out as plasma levels, which is a marker and not an outcome. Formulators pair them for antioxidant breadth rather than for a demonstrated combined effect.

Resveratrol is heavily glucuronidated and sulfated on first pass, the same route that limits flavonol exposure. Combining polyphenols spreads that enzymatic load across more substrates. Products aimed at cellular maintenance commonly carry both, though the pairing rests on overlapping pharmacokinetics rather than on a combination trial.

Pterostilbene carries two methyl ethers where resveratrol carries hydroxyls, which slows conjugation and raises circulating levels. Alongside flavonols it contributes to the same antioxidant and stress-response themes brands build these blends around. No combination study anchors the pairing; the basis is comparative pharmacology.

Dihydrolipoic acid, the reduced form of alpha-lipoic acid, returns oxidised antioxidants to their active state. Flavonols that have quenched a radical become flavonoid radicals themselves, and a reducing partner in the same compartment shortens that state. The relationship is established redox chemistry measured in vitro, not a clinical outcome.

Alpha-tocopherol sits inside the membrane bilayer and stops lipid peroxidation chains. Flavonols are more polar and act at the membrane surface and in cytosol. Polyphenols can reduce the tocopheroxyl radical back to tocopherol, which is a well-described in vitro recycling step and the reason the two are formulated together.

When a flavonol is oxidised to a quinone or quinone methide it is captured by glutathione and cleared as a conjugate. High flavonoid loads therefore draw on the cellular glutathione pool. Co-supplying glutathione or its precursors supports that clearance step. This is established detoxification biochemistry rather than a tested combination.

N-acetylcysteine supplies cysteine, the rate-limiting amino acid for glutathione synthesis. Because oxidised flavonol intermediates are handled through glutathione conjugation, cysteine availability sits upstream of that route. The link is settled biochemistry; no trial has measured the pair together at supplement doses.

The catechol and 3-hydroxy-4-keto arrangements on quercetin and fisetin bind ferric iron tightly, forming complexes that do not cross the enterocyte the way free ionic iron does. The same chemistry is why tea polyphenols lower non-heme iron uptake from a meal. Separating a flavonoid dose from an iron dose by a couple of hours is the usual formulation answer. This is textbook mineral-polyphenol interaction.

Calcium salts raise luminal pH and bind polyphenol hydroxyl groups, producing less soluble complexes. The effect is smaller than with iron because calcium binds flavonols weakly. Spacing a high-dose calcium supplement from a flavonoid dose is a reasonable formulation habit rather than a documented requirement.

Both flavonols in this pairing are practically insoluble in water, so the amount dissolved in the intestinal lumen caps what can be taken up. A medium-chain lipid vehicle keeps more of the dose in solution and promotes micellar handling. Softgel and oil-suspension products use this routinely. The endpoint is plasma exposure, a marker, not a clinical result.

A phytosome is a flavonoid molecule hydrogen bonded to the polar head of a phosphatidylcholine molecule, which gives the complex amphiphilic character. That form disperses in the gut where the raw aglycone would not. Phospholipid complexes of quercetin are a commercial reality and the mechanism is well characterised in formulation science.

Spermidine is a polyamine linked in preclinical work to autophagy induction, and flavonols touch overlapping stress-response signalling. Products combine them for that shared theme. The grounding is mechanistic and preclinical; no human combination data supports the pairing.

Urolithin A is a microbial metabolite of ellagitannins and is studied for mitochondrial quality control. Flavonols in this stack are aimed at the same broad maintenance theme in supplement formulation. The link is thematic and mechanistic; it has not been measured as a combination.

Quercetin inhibits the efflux transporters and the catechol O-methyltransferase activity that limit catechin exposure, and catechins occupy the same UGT isoforms flavonols use. The result can be higher exposure to both or displacement of one, depending on dose and timing. Read it as a pharmacokinetic interaction rather than an effect on any body process.

Nicotinic acid is converted to NAD through the Preiss-Handler route, so it addresses the same coenzyme pool as the ribosides and mononucleotides already stored against this stack. Pairing an NAD precursor with flavonols is the common architecture of these products. The rationale is established biochemistry for the precursor step, not a tested combination.